Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease

Pediatric Infectious Disease Journal

Volumn 23, Issue 6, 2004, Pages 571-574

  Majda Stanislawska, Ewa ^a   Bednarek, Małgorzata ^a   Kuydowicz, Jan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Children; Hepatitis A vaccine; Hepatitis B; Hepatitis C

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ARTICLE; CHILD; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VACCINES, INACTIVATED;

EID: 3042594452     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000130076.33497.6c     Document Type: Article

References (28)

1. Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastroenterol Belg. 1998;6:175-182.
2. Majda-Stanislawska E, Omulecka A, Szaflik I. Clinical picture of chronic hepatitis C in children: Polish experience. Acta Gastroenterol Belg. 2000;64:20-24.
3. CDC. Prevention of hepatitis A through active and passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1996;45:1-30.
4. CDC. Prevention of hepatitis A through active and passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-37.
5. Wu JC, Chen CL, Hou MC, Chen TZ, Lee SD, Lo KJ. Multiple viral infections as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction. Hepatology. 1994;19:836-840.
6. Pramoolsinsap C, Poovorawan Y, Hirsh P, Busagom N, Attamasirikul K. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol. 1999;93:745-751.
7. Williams L, Bell B, Kaluba J, Shapiro C. Association between chronic liver disease and death from hepatitis A, United States 1989-1992 [Abstract 39]. In: IX Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, Italy, April 21-25, 1996.
8. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286-290.
9. Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:1771-1772.
10. Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J Viral Hepat. 2000;7(suppl 1):7-8.
11. Locarnini S. A virological perspective on the need for vaccination. J Viral Hepatol. 2000;7(suppl 1):5-6.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer P. Classification of chronic hepatitis C: diagnosis, grading and staging. Hepatology. 1994;19:1513-520.
13. Abbot Axsym System, HAVAB 2.0 Quantitative. Abbot Park, IL Abbott Laboratories Diagnostic Division; 1999:List 3C76:1-6.
14. De Fraites RB, Feighner BH, Binn N, et al. Immunization of US soldiers with a two-dose primary series of inactivated hepatitis A vaccine: early immune response, persistence of antibody, and response to a third dose at 1 year. J Infect Dis. 1995;171(suppl 1):61-69.
15. Victor J, Knudsen JD, Nielsen LP, et al. Hepatitis A vaccine: a new convenient single-dose schedule with booster when long-term immunization is warranted. Vaccine. 1994;12:1327-1329.
16. Miller WJ, Clark H, Hurni W, Kuter B, Schofield T, Nalin D. Sensitive assays for hepatitis A antibodies. J Med Virol. 1993;4:201-204.
17. Delem AD. Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response. Biologicals. 1992;20: 289-291.
18. Kanra G, Yalcin SS, Kara A, Ozmert E, Yurdakok K. Hepatitis A booster vaccine in children after infant immunization. Pediatr Infect Dis J. 2002;21:727-730.
19. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994;44:446-451.
20. De Febres OC, de Petrola MC, de Escalona LC, et al. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine. 2000;18:656-664.
21. Lee SD, Chan CY, Yu CM, Wang YJ, Chang FY. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol. 1997;52:215-218.
22. Michielsen PP, Van Damme P. Hepatitis vaccination in patients with chronic liver disease. Acta Gastrenterol Belg. 2000;63:1-4.
23. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;7:881-888.
24. Keeffe EB, McMahon BJ, Koff RS, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Gastroenterology. 1996;110:A1231.
25. Ferreira CT, Da Silveira TR, Vieira SM, Taniguchi A, Pereira-Lima J. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr. 2003;37:258-261.
26. Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology. 2001;34:28-31.
27. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol. 2001;63:1-7.
28. Wiedermann G, Kundi M, Ambrosch F. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop. 1998;69:121-125.